Assessment of pomegranate whitening cream on melasma

consideration of clinical safety and efficacy of topical formulation of polyphenolic extract of punica granatum on patients with mild to moderate forms of melasma

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20161207031288N6

Enrollment

Registered

2020-10-12

Start date

2020-10-22

Completion date

Unknown

Last updated

2020-11-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Melasma. Chloasma

Interventions

Intervention group: Approving the whitening cream on patient with mild to moderate melasma (single arm study).

Eligibility

Sex/Gender

All

Age

18 Years to 50 Years

Inclusion criteria

Inclusion criteria: Mild to moderate melasma with minimum grade of Melasma area and severity index = 1 Age range 18-50 Signing consent form, voluntarily and knowingly

Exclusion criteria

Exclusion criteria: Pregnancy or lactation Using oral corticosteroids or isotretinoin within 28 days prior to the study Any active skin disease at test area including rosacea, eczema, atrophy, acne Using any light sensitizing medicine within 3 months prior to the study Use of topical lightening products like alpha hydroxy acid, beta hydroxy acid, and retinoid component within 21 days prior to the study Documented allergy to components of the cream History of laser treatment or dermabrasion or deep facial peeling within the past 3 months prior to the study Using contraceptive or hormonal medicines

Design outcomes

Secondary

Measure	Time frame
Skin pH. Timepoint: At the beginning (before start of the intervention) and 4 and 8 weeks after start of the intervention. Method of measurement: Cutometer MPA 580.;Skin sebum. Timepoint: At the beginning (before start of the intervention) and 4 and 8 weeks after start of the intervention. Method of measurement: Cutometer MPA 580.;Skin melanin and erythem. Timepoint: At the beginning (before start of the intervention) and 4 and 8 weeks after start of the intervention. Method of measurement: Cutometer MPA 580.;Transepidermal watre loss. Timepoint: At the beginning (before start of the intervention) and 4 and 8 weeks after start of the intervention. Method of measurement: Cutometer MPA 580.;Size and value of skin spot. Timepoint: At the beginning (before start of the intervention) and 4 and 8 weeks after start of the intervention. Method of measurement: Visio face device.	—

Measure

Time frame

Skin pH. Timepoint: At the beginning (before start of the intervention) and 4 and 8 weeks after start of the intervention. Method of measurement: Cutometer MPA 580.;Skin sebum. Timepoint: At the beginning (before start of the intervention) and 4 and 8 weeks after start of the intervention. Method of measurement: Cutometer MPA 580.;Skin melanin and erythem. Timepoint: At the beginning (before start of the intervention) and 4 and 8 weeks after start of the intervention. Method of measurement: Cutometer MPA 580.;Transepidermal watre loss. Timepoint: At the beginning (before start of the intervention) and 4 and 8 weeks after start of the intervention. Method of measurement: Cutometer MPA 580.;Size and value of skin spot. Timepoint: At the beginning (before start of the intervention) and 4 and 8 weeks after start of the intervention. Method of measurement: Visio face device.

—

Primary

Measure	Time frame
Modified melasma severity index. Timepoint: Before intervention, 4 weeks later, 8 weeks after intervention. Method of measurement: Modified Melasma Area and Severity Index.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSaman Ahmad Nasrollahi

Center For Research And Training In Skin Diseases And Leprosy

snasrollahi@tums.ac.ir+98 21 8896 0880

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026